Sean D Sullivan, Kai Yeung, Carol Vogeler, Scott D Ramsey, Edward Wong, Chad O Murphy, Dan Danielson, David L Veenstra, Louis P Garrison, Wylie Burke, John B Watkins
BACKGROUND: Value-based insurance design attempts to align drug copayment tier with value rather than cost. Previous implementations of value-based insurance design have lowered copayments for drugs indicated for select "high value" conditions and have found modest improvements in medication adherence. However, these implementations have generally not resulted in cost savings to the health plan, suggesting a need for increased copayments for "low value" drugs. Further, previous implementations have assigned equal copayment reductions to all drugs within a therapeutic area without assessing the value of individual drugs...
April 2015: Journal of Managed Care & Specialty Pharmacy